Your browser doesn't support javascript.
loading
Predicting SARS-CoV-2 variant spread in a completely seropositive population using semi-quantitative antibody measurements in blood donors
Lewis F Buss; Carlos A. Prete Jr.; Charles Whittaker; Tassila Salomon; Marcio K Oikawa; Rafael H. M. Pereira; Isabel C. G. Moura; Lucas Delerino; Rafael F. O. Franca; Fabio Miyajima; Alfredo Mendrone-Junior; Cesar de Almeida Neto; Nanci A. Salles; Suzete C. Ferreira; Karine A Fladzinski; Luana M. de Souza; Luciane Schier; Patricia M. Inoue; Lilyane A. Xabregas; Myuki A. E. Crispim; Nelson Fraiji; Luciana M. B. Carlos; Veridiana Pessoa; Maisa A. Riberio; Rosenvaldo E. de Souza; Anna F Cavalcante; Maria I. B. Valenca; Maria V da Silva; Esther Lopes; Luiz A. Filho; Sheila O. G. Mateos; Gabrielle T. Nunes; David Schlesinger; Sonia Nunes; Alexander L. Silva-Junior; Marcia C. Castro; Vitor H. Nascimento; Christopher Dye; Michael P. Busch; Nuno R. Faria; Ester C Sabino.
Afiliação
  • Lewis F Buss; Imperial College London
  • Carlos A. Prete Jr.; Department of Electronic Systems Engineering, University of Sao Paulo, Brazil
  • Charles Whittaker; MRC Centre for Global Infectious Disease Analysis, Imperial College London, UK
  • Tassila Salomon; Faculdade Ciencias Medicas de Minas Gerais, Brazil
  • Marcio K Oikawa; Universidade Federal do ABC, Brazil
  • Rafael H. M. Pereira; Institute for Applied Economic Research (Ipea)
  • Isabel C. G. Moura; Faculdade Ciencias Medicas de Minas Gerais, Brazil
  • Lucas Delerino; Fundacao Oswaldo Cruz, Brazil
  • Rafael F. O. Franca; Fundacao Oswaldo Cruz, Brazil
  • Fabio Miyajima; Federal University of Ceara: Universidade Federal do Ceara
  • Alfredo Mendrone-Junior; Fundacao Pro Sangue Hemocentro de Sao Paulo (FPS), Brazil
  • Cesar de Almeida Neto; Fundacao Pro Sangue Hemocentro de Sao Paulo (FPS), Brazil
  • Nanci A. Salles; Fundacao Pro Sangue Hemocentro de Sao Paulo (FPS), Brazil
  • Suzete C. Ferreira; Fundacao Pro Sangue Hemocentro de Sao Paulo (FPS), Brazil
  • Karine A Fladzinski; Centro de Hematologia e Hemoterapia do Parana (HEMEPAR), Brazil
  • Luana M. de Souza; Centro de Hematologia e Hemoterapia do Parana (HEMEPAR), Brazil
  • Luciane Schier; Centro de Hematologia e Hemoterapia do Parana (HEMEPAR), Brazil
  • Patricia M. Inoue; Centro de Hematologia e Hemoterapia do Parana (HEMEPAR), Brazil
  • Lilyane A. Xabregas; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Brazil
  • Myuki A. E. Crispim; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Brazil
  • Nelson Fraiji; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Brazil
  • Luciana M. B. Carlos; Centro de Hematologia e Hemoterapia do Ceara (HEMOCE), Brazil
  • Veridiana Pessoa; Centro de Hematologia e Hemoterapia do Ceara (HEMOCE), Brazil
  • Maisa A. Riberio; Fundacao HEMOMINAS, Brazil
  • Rosenvaldo E. de Souza; Fundacao HEMOMINAS, Brazil
  • Anna F Cavalcante; Fundacao de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Brazil
  • Maria I. B. Valenca; Fundacao de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Brazil
  • Maria V da Silva; Fundacao de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Brazil
  • Esther Lopes; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Brazil
  • Luiz A. Filho; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Brazil
  • Sheila O. G. Mateos; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Brazil
  • Gabrielle T. Nunes; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Brazil
  • David Schlesinger; Mendelics, Brazil
  • Sonia Nunes; Fundacao HEMOMINAS, Brazil
  • Alexander L. Silva-Junior; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Brazil & Universidade Federal do Amazonas, Brazil & Centro Universitario do Norte, Brazil
  • Marcia C. Castro; Harvard TH Chan School of Public Health
  • Vitor H. Nascimento; Department of Electronic Systems Engineering, University of Sao Paulo, Brazil
  • Christopher Dye; Department of Zoology, University of Oxford, UK
  • Michael P. Busch; Vitalant Research Institute, USA & University of California San Francisco, USA
  • Nuno R. Faria; MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK & Departamento de Molestias I
  • Ester C Sabino; Instituto de Medicina Tropical, Universidade de Sao Paulo, Brazil
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22276483
ABSTRACT
BackgroundSARS-CoV-2 serologic surveys estimate the proportion of the population with antibodies against historical variants which nears 100% in many settings. New analytic approaches are required to exploit the full information in serosurvey data. MethodUsing a SARS-CoV-2 anti-Spike (S) protein chemiluminescent microparticle assay, we attained a semi-quantitative measurement of population IgG titres in serial cross-sectional monthly samples of routine blood donations across seven Brazilian state capitals (March 2021-November 2021). In an ecological analysis (unit of

analysis:

age-city-calendar month) we assessed the relative contributions of prior attack rate and vaccination to antibody titre in blood donors. We compared blood donor anti-S titre across the seven cities during the growth phase of the Delta variant of concern (VOC) and use this to predict the resulting age-standardized incidence of severe COVID-19 cases. ResultsOn average we tested 780 samples per month in each location. Seroprevalence rose to >95% across all seven capitals by November 2021. Driven proximally by vaccination, mean antibody titre increased 16-fold over the study. The extent of prior natural infection shaped this process, with the greatest increases in antibody titres occurring in cities with the highest prior attack rates. Mean anti-S IgG was a strong predictor (adjusted R2 =0.89) of the number of severe cases caused by the Delta VOC in the seven cities. ConclusionsSemi-quantitative anti-S antibody titres are informative about prior exposure and vaccination coverage and can inform on the potential impact of future SARS-CoV-2 variants. SummaryIn the face of near 100% SARS-CoV-2 seroprevalence, we show that average semi-quantitative anti-S titre predicted the extent of the Delta variants spread in Brazil. This is a valuable metric for future seroprevalence studies.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Observational_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Observational_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint